Protagenic Therapeutics Appoints William Nichols, Jr. as President, Bolstering Commercial Leadership

summarizeSummary

Protagenic Therapeutics appointed William Nichols, Jr., a veteran with commercial leadership experience from bluebird bio and Bristol-Myers Squibb, as its new President.

check_boxKey Events

• New President Appointed

  William (Bill) Nichols, Jr., age 51, was appointed as President of Protagenic Therapeutics, effective February 3, 2026.

• Extensive Industry Experience

  Mr. Nichols brings senior commercial leadership experience from bluebird bio, Dova Pharmaceuticals (now Sobi), and Bristol-Myers Squibb.

• Compensation Package

  Mr. Nichols will receive an annual base salary of $350,000, an annual target bonus of 40% of his base salary, and an option grant equal to approximately 1.0% of the company's fully diluted share count.

auto_awesomeAnalysis

The appointment of William Nichols, Jr. as President brings significant commercial leadership experience from established biopharmaceutical companies to Protagenic Therapeutics. For a micro-cap company, securing a seasoned executive like Mr. Nichols is a material development that could signal a strategic focus on advancing its pipeline or preparing for commercialization. His compensation package, including a substantial option grant, aligns his incentives with long-term shareholder value, albeit with potential future dilution.